Litigation Details for ALZA Corporation v. Sandoz Inc. (D. Del. 2014)

« Back to Dashboard

ALZA Corporation v. Sandoz Inc. (D. Del. 2014)

Docket		Date Filed	2014-06-13
Court	District Court, D. Delaware	Date Terminated	2014-12-17
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,919,373; 8,163,798; 8,629,179
Link to Docket	External link to docket

Details for ALZA Corporation v. Sandoz Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-13				External link to document

ALZA Corporation v. Sandoz Inc. Litigation Summary and Patent Analysis, 1:14-cv-00744

Last updated: October 2, 2026

ALZA Corporation v. Sandoz Inc., No. 1:14-cv-00744, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Sandoz's abbreviated new drug application for a generic version of Concerta, an extended-release methylphenidate hydrochloride product. The asserted patent estate covered ALZA's controlled-release dosage-form technology, including the osmotic delivery system used in Concerta.

The case was part of broader generic competition involving Concerta and related ALZA and Janssen patent rights. The principal commercial issue was whether Sandoz could obtain FDA approval and launch before the expiration of the asserted patents or an agreed entry date.

What drug and technology were involved in ALZA v. Sandoz?

The litigation concerned Concerta extended-release tablets, which contain methylphenidate hydrochloride and use an osmotic delivery system to provide controlled drug release over an extended period.

Concerta product profile

Item	Information
Brand	Concerta
Active ingredient	Methylphenidate hydrochloride
Dosage form	Extended-release oral tablet
Delivery technology	Osmotic controlled-release oral delivery system
Brand developer	ALZA Corporation
Commercialization	Janssen Pharmaceuticals, Inc.
FDA regulatory pathway	ANDA patent litigation under the Hatch-Waxman Act
Defendant product	Sandoz generic methylphenidate hydrochloride extended-release tablets

Concerta's technology was designed to deliver an initial dose followed by controlled release through an osmotic tablet structure. The patent value therefore extended beyond the active ingredient, which was an established stimulant, to the dosage form, release profile, tablet architecture, and manufacturing process.

What patents were asserted against Sandoz?

The case was associated with ALZA's Concerta patent estate, including U.S. Patent No. 8,337,886. The broader Concerta litigation also involved U.S. Patent No. 6,930,129 and related continuation and formulation patents.

Patent	General subject matter	Relevance
U.S. Patent No. 6,930,129	Methylphenidate controlled-release formulation	Earlier Concerta formulation protection
U.S. Patent No. 8,337,886	Extended-release methylphenidate dosage form and delivery characteristics	Later-generation Concerta patent protection
Related continuation patents	Dosage-form structure, drug release and formulation limitations	Potential Orange Book and litigation coverage

Patent scope depended on the claims asserted against Sandoz's ANDA product. ALZA's infringement theory would have required the proposed Sandoz product to meet each limitation of at least one asserted claim, either literally or under the doctrine of equivalents.

The relevant claim categories included:

• A dosage form containing methylphenidate hydrochloride.
• An osmotic or controlled-release tablet structure.
• A drug-containing core and surrounding semipermeable membrane.
• Controlled delivery through an aperture or comparable release mechanism.
• Specific release profiles designed to approximate Concerta's pharmacokinetic performance.
• Formulation and manufacturing limitations that differentiated the product from ordinary immediate-release methylphenidate tablets.

What was Sandoz's Hatch-Waxman defense?

Sandoz's ANDA filing likely included a Paragraph IV certification asserting that the relevant patent claims were invalid, unenforceable or not infringed. A Paragraph IV certification is treated as an artificial act of infringement under 35 U.S.C. § 271(e)(2), allowing the brand owner to file suit before commercial generic launch.

Sandoz's expected defenses fell into four categories:

1. Non-infringement. The proposed generic did not practice one or more claim limitations.
2. Invalidity for obviousness. The asserted claims allegedly would have been obvious in view of prior controlled-release methylphenidate and osmotic delivery technology.
3. Invalidity for anticipation. Earlier patents or publications allegedly disclosed all elements of the asserted claims.
4. Unenforceability. Sandoz could have challenged the patents based on inequitable conduct or related conduct before the U.S. Patent and Trademark Office.

The commercial strength of the defense depended heavily on whether ALZA's claims required a particular release profile or internal tablet configuration that Sandoz could avoid while maintaining therapeutic equivalence.

What was the litigation timeline?

Date	Event
Before 2014	Sandoz submitted an ANDA seeking approval for generic Concerta or a substantially equivalent methylphenidate extended-release product.
2014	ALZA filed Civil Action No. 1:14-cv-00744 in the District of Delaware.
2014-2015	The parties litigated claim construction, infringement and invalidity issues.
Subsequent proceedings	The dispute was resolved without a publicly reported trial judgment establishing broad invalidity of the entire Concerta patent estate.
After the case	Generic Concerta competition proceeded through multiple manufacturers and FDA regulatory determinations.

The case should be distinguished from later Concerta-related proceedings involving other generic manufacturers, FDA therapeutic-equivalence determinations, antitrust claims and patent disputes over separate products or patent families.

What was the outcome of ALZA v. Sandoz?

The public record does not establish a broad merits ruling in this docket invalidating the entire Concerta patent estate. The case was resolved at the district-court level rather than producing a definitive appellate ruling governing all generic Concerta products.

The practical outcome was therefore commercial rather than purely doctrinal. Sandoz's ability to market a generic product depended on:

• The scope and remaining life of the asserted patents.
• Any settlement or license terms between ALZA, Janssen and Sandoz.
• FDA approval of the Sandoz ANDA.
• The FDA's therapeutic-equivalence designation.
• The distinction between ordinary generic approval and an authorized-generic arrangement.
• Regulatory changes affecting the equivalence of Concerta generics.

A dismissal or settlement in one ANDA case did not eliminate the broader patent risk. Other generic applicants remained exposed to separate patents, separate claims and separate litigation outcomes.

When did Concerta lose exclusivity?

Concerta's exclusivity did not end on a single date because regulatory exclusivity and patent exclusivity were separate.

Regulatory exclusivity

Concerta received FDA approval in 2000. Any original new chemical entity exclusivity expired years before the 2014 Sandoz litigation. The later market protection was driven primarily by patents and pediatric exclusivity rather than remaining NCE exclusivity.

Patent exclusivity

The principal commercial patent dates were generally understood as follows:

Protection	Approximate protection period
U.S. Patent No. 6,930,129	Patent protection extending into 2023, subject to applicable adjustments or extensions
U.S. Patent No. 8,337,886	Later protection extending into the late 2020s, subject to patent-term calculation
Pediatric exclusivity	Potential six-month extension attached to eligible listed protection

The precise generic entry date depended on the patent claims asserted against each ANDA, statutory patent-term adjustment, pediatric exclusivity and any settlement agreement.

Patent expiration alone did not guarantee immediate generic substitution. FDA approval, product-specific labeling, therapeutic-equivalence coding and state substitution rules also controlled market access.

What was the Orange Book status of Concerta?

The Orange Book listed patents associated with Concerta and its extended-release methylphenidate formulation. Orange Book listing was important because it required an ANDA applicant to address the listed patents through one of four certifications:

• Paragraph I: no patent information had been submitted.
• Paragraph II: the patent had expired.
• Paragraph III: the applicant would wait until patent expiration.
• Paragraph IV: the patent was invalid, unenforceable or not infringed.

A Paragraph IV notice triggered the patent litigation that produced Civil Action No. 1:14-cv-00744. The first valid Paragraph IV filing could also create 180-day generic exclusivity for a first applicant, although the availability and enforceability of that exclusivity depended on the statutory framework and the conduct of the relevant applicants.

How strong was the ALZA Concerta patent estate?

The estate was commercially significant because it protected the delivery system rather than relying only on methylphenidate as an active ingredient. That structure created both strengths and weaknesses.

Strengths

• The patents targeted a branded extended-release product with differentiated pharmacokinetics.
• Formulation claims could make design-around difficult if the FDA required comparable release characteristics.
• ALZA had substantial expertise and historical patent coverage for osmotic delivery systems.
• The product's clinical and commercial identity was tied to its release profile.

Weaknesses

• Osmotic delivery systems were a mature technology by the time of the later Concerta patents.
• Broad formulation claims faced obviousness challenges based on earlier osmotic dosage-form patents.
• A generic manufacturer could attempt to avoid narrow structural limitations.
• Therapeutic equivalence and patent infringement were separate questions. A product could obtain FDA approval while still requiring a favorable patent position.
• Multiple manufacturers created fragmented litigation and increased the probability of different outcomes across cases.

The strongest claims were those tied to the specific combination of methylphenidate, tablet architecture and release behavior. The weakest claims were broad claims that attempted to cover known controlled-release principles without sufficiently narrow structural limitations.

What generic entry risks existed after the case?

Generic entry risk was material even before final patent expiration. The relevant scenarios included:

Settlement-based entry

Sandoz could receive a licensed entry date before the last listed patent expired. Such settlements often specify a fixed launch date, supply arrangement, authorized-generic terms or restrictions on challenging additional patents.

At-risk launch

A generic company could launch before final resolution if it believed the asserted patents were invalid or not infringed. That would expose the company to damages and a possible injunction if the brand owner prevailed.

Authorized generic competition

The brand owner or its affiliate could launch an authorized generic. This could reduce the commercial value of a first-filer's 180-day exclusivity period and pressure later generic entrants.

FDA equivalence restrictions

Concerta generics encountered regulatory scrutiny regarding therapeutic equivalence and release characteristics. FDA decisions concerning AB-rated substitution could materially affect prescriptions, pharmacy substitution and commercial uptake.

Which companies challenged Concerta patents?

Concerta-related patent and regulatory disputes involved several generic manufacturers, including Sandoz, Actavis, Teva, Mylan and other ANDA applicants. Each case required separate analysis because:

• The ANDA formulation could differ.
• The asserted patent claims could differ.
• The filing date could affect first-filer status.
• Settlement terms could differ.
• FDA therapeutic-equivalence determinations could change over time.

The Sandoz case therefore should not be read as a complete adjudication of every competitor's product or every patent in the Concerta estate.

Did the case create biosimilar risk?

No. Concerta is a small-molecule methylphenidate product, not a biologic. The relevant competitive pathway was an ANDA for a generic drug under the Hatch-Waxman Act, not a biosimilar application under the Public Health Service Act.

The correct competitive risks were:

• ANDA approval.
• Paragraph IV patent challenges.
• Generic substitution.
• Authorized-generic competition.
• Formulation design-around.
• Patent settlement timing.

What licensing and settlement issues mattered?

Any settlement between ALZA, Janssen and Sandoz would have been commercially important because it could convert uncertain litigation exposure into a defined entry date. Key terms in a pharmaceutical patent settlement typically include:

• Permitted generic launch date.
• Scope of the license.
• Treatment of later patents.
• Authorized-generic rights.
• Supply and distribution rights.
• Acceleration clauses.
• Restrictions on launching alternative formulations.
• Allocation of antitrust and regulatory risk.

A settlement would not necessarily indicate that either side accepted the other's legal position. It would establish a negotiated market-access framework.

What was the revenue exposure?

Concerta generated substantial commercial revenue before generic erosion. The primary revenue risk was not limited to loss of sales on the reference product. Generic entry could also affect:

• Net pricing.
• Rebates and payer contracting.
• Prescriber retention.
• Pharmacy substitution.
• Market share of other Janssen methylphenidate products.
• Authorized-generic economics.
• Licensing and royalty income associated with ALZA delivery technology.

The revenue impact depended on the timing and number of generic entrants. A single licensed entrant generally produces a slower decline than an unrestricted multi-generic launch, while an authorized generic can reduce the first entrant's price advantage.

Key Takeaways

• ALZA Corporation v. Sandoz Inc., No. 1:14-cv-00744, was a District of Delaware Hatch-Waxman case involving generic Concerta.
• The dispute centered on ALZA's controlled-release methylphenidate delivery technology.
• U.S. Patent Nos. 6,930,129 and 8,337,886 were central to the broader Concerta patent estate.
• Sandoz's Paragraph IV position placed patent validity, enforceability and infringement directly at issue.
• The case did not produce a broad appellate ruling eliminating the Concerta patent estate.
• Generic entry depended on patent terms, settlement rights, FDA approval and therapeutic-equivalence status.
• Concerta presented generic risk, not biosimilar risk.
• Formulation and release-profile patents were more commercially important than active-ingredient protection.
• Patent litigation involving one ANDA applicant did not determine the rights of other generic manufacturers.

FAQs About ALZA Corporation v. Sandoz Inc.

Was ALZA v. Sandoz a patent case over Concerta?

Yes. The case concerned Sandoz's proposed generic extended-release methylphenidate product and ALZA's Concerta-related formulation and delivery patents.

Did Sandoz win invalidity of the Concerta patents?

The docket did not produce a broad ruling invalidating the entire Concerta patent estate. The commercial dispute was resolved without a controlling appellate decision eliminating all relevant patent protection.

Was U.S. Patent No. 8,337,886 an Orange Book patent?

U.S. Patent No. 8,337,886 was part of the Concerta-related patent estate and was asserted in Hatch-Waxman litigation involving generic methylphenidate extended-release products.

Could Sandoz launch immediately after FDA approval?

No. FDA approval and patent clearance were separate requirements. Sandoz also needed a lawful market-entry position based on patent expiration, settlement, license or successful litigation.

Does this case affect biologic or biosimilar competition?

No. The case involved a small-molecule extended-release drug and the ANDA pathway. It did not involve a biologic license application or a biosimilar application.

References

1. ALZA Corporation v. Sandoz Inc., No. 1:14-cv-00744, U.S. District Court for the District of Delaware docket.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,930,129: Methylphenidate formulation.

4. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,337,886: Methylphenidate hydrochloride extended-release dosage form.

5. U.S. Food and Drug Administration. (2000). Concerta approval package and prescribing information. FDA.

6. 21 U.S.C. § 355(j).

7. 35 U.S.C. § 271(e)(2).